Dupixent® (dupilumab) late-breaking positive pivotal data in bullous pemphigoid presented at aad

Five times more adults on dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch

REGN Ratings Summary

REGN Quant Ranking